NCT07649954
A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary and study completion dates changed from estimate of Oct 2026 to Oct 5, 2026
Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 6 entries
- Enrollment closed, study ongoing
- Primary and study completion dates: Sep 2026 to Oct 2026
- Site details revised
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jun 28, 2026 to Jun 23, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum Observed Plasma Concentration (Cmax) of Nacresertib
Timeframe: Up to Day 12
Time to Cmax (Tmax) of Nacresertib
Timeframe: Up to Day 12
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib
Timeframe: Up to Day 12
AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib
Timeframe: Up to Day 12
Terminal Phase Elimination Rate Constant (Beta) of Nacresertib
Timeframe: Up to Day 12
Terminal Phase Elimination Half-Life (t1/2) of Nacresertib
Timeframe: Up to Day 12
Arms and interventions
Period 1: Nacresertib OnlyExperimental
Participant receives single dose of Nacresertib administered on Day 1
Period 2: Nacresertib and ItraconazoleExperimental
Participant will receive itraconazole multiple times on Day 1, followed by a single dose of itraconazole on Days 2 through 11. Participants will also receive a single oral dose of Nacresertib on Day 4.
Drugs: Nacresertib, Itraconazole
Sites
1 site in 1 country
- Acpru /Id# 282339Grayslake, Illinois, United States